KRAS and ovarian carcinoma: SLC1A5 is highly expressed in diverse solid tumors, including triple-negative breast cancer (TNBC) [32], KRAS-mutated colorectal cancer (CRC) [33], esophageal cancer [30], gastric cancer [34], lung cancer [35], ovarian cancer [36], prostate cancer [37], renal cell [38], head and neck squamous cell carcinoma (HNSCC) [39] and hepatocellular carcinoma [40].